BioNTech Completes CureVac Acquisition, Ending Independent Trading Era
12.01.2026 - 09:55:04
The era of CureVac as a publicly traded company has concluded. BioNTech SE has finalized its acquisition of the mRNA pioneer, removing CureVac’s shares from the Nasdaq exchange. The move transforms the long-competitive firm into a fully integrated subsidiary, bringing all its patents, manufacturing capabilities, and associated legal matters under BioNTech’s corporate umbrella. For former shareholders, the financial chapter is closed, while BioNTech now enters a critical operational integration phase.
Through this transaction, BioNTech secures several key strategic components from CureVac. These include a state-of-the-art production facility located in Tübingen, Germany, and proprietary “RNA Printer” modules designed for automated mRNA vaccine manufacturing. The acquisition also delivers CureVac’s Read more...
